Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.66 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396705 | 0.85 | KMT2A (0.77) | KMT2APKMTSHRL3MBTL1RAB9A | |
| SCHEMBL395198 | 0.84 | KMT2A (0.75) | KMT2APKMTSHRL3MBTL1RAB9A | |
| SCHEMBL3921818 | 0.83 | TSHR (0.97) | KMT2APKMTSHRL3MBTL1MEN1 | |
| SCHEMBL6646760 | 0.83 | KMT2A (0.67) | KMT2APKMTSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL396774 | 0.83 | POLB (0.70) | KMT2APKMTSHRL3MBTL1MEN1 | |
| SCHEMBL1708867 | 0.82 | TSHR (1.00) | KMT2APKMTSHRL3MBTL1MEN1 | |
| SCHEMBL5875707 | 0.81 | KMT2A (0.71) | KMT2APKMTSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL6330574 | 0.81 | KMT2A (0.58) | KMT2APKMTSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL4715140 | 0.80 | TSHR (0.71) | KMT2APKMTSHRL3MBTL1MEN1 | |
| SCHEMBL5469321 | 0.80 | ALDH1A1 (0.59) | PKMTSHRAPOBEC3AAPOBEC3GNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994115-B1 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | PFIZER LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2003-04-10 | — | — | US | disclosed |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2001-07-26 | — | — | US | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | KMT2A 2876/4885PKM 488/4885TSHR 4131/4885 |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | KMT2A 2876/4885PKM 488/4885TSHR 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.